Neumora Therapeutics
NMRA
104 hedge funds and large institutions have $907M invested in Neumora Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 35 increasing their positions, 22 reducing their positions, and 11 closing their positions.
100% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 11
59% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 22
55% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $9.43M
45% more capital invested
Capital invested by funds: $627M → $907M (+$280M)
12% more funds holding
Funds holding: 93 → 104 (+11)
2.9% more ownership
Funds ownership: 40.01% → 42.92% (+2.9%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
BlackRock
New York
|
+$18.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.25M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.1M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.89M |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$27.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.74M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.91M |
NMRA Hedge Fund Activity: Q3 2024 in Review
104 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q3 2024, worth a combined $907M — up 45% from $627M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NMRA positions and 11 closed out — a net gain of 11 holders — while 35 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $18.5M. The largest seller was Artal Group, exiting entirely with an estimated $27.8M sold.
- 104 institutional investors held Neumora Therapeutics (NMRA) as of Q3 2024, up from 93 in Q2 2024.
- Funds reported $907M of Neumora Therapeutics stock for Q3 2024, up 45% quarter-over-quarter.
- 22 funds opened new Neumora Therapeutics positions in Q3 2024 and 11 closed out, a net change of +11 holders.
- The largest Neumora Therapeutics buyer in Q3 2024 was BlackRock, an estimated $18.5M added.
- The largest Neumora Therapeutics seller in Q3 2024 was Artal Group, an estimated $27.8M sold.
Based on aggregated 13F filings for Q3 2024.